ArticleNeurobiology of disease2016
Equilibrative nucleoside transporter ENT1 as a biomarker of Huntington disease.
Open access · greenAbstract read
In one paragraph
Article in Neurobiology of disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
0numbers the graph read from it
0cells of the map it votes in
15citing papers in PubMed
2.0field-weighted citation impact, top 15% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 22 citations in OpenAlex.
- The expression profile of type 1 equilibrative nucleoside transporter in aged C57BL/6J mouse brain.Acta biochimica et biophysica Sinica · 2025Article
- A Novel Huntington's Disease Assessment Platform to Support Future Drug Discovery and Development.International journal of molecular sciences · 2022Article
- Emerging roles of dysregulated adenosine homeostasis in brain disorders with a specific focus on neurodegenerative diseases.Journal of biomedical science · 2021Review
- DNA Methylation and Expression Profiles of Whole Blood in Parkinson's Disease.Frontiers in genetics · 2021Article
- Metabolic Aspects of Adenosine Functions in the Brain.Frontiers in pharmacology · 2021Review
- Purinergic Signaling in the Pathophysiology and Treatment of Huntington's Disease.Frontiers in neuroscience · 2021Review
- Indirect Medium Spiny Neurons in the Dorsomedial Striatum Regulate Ethanol-Containing Conditioned Reward Seeking.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019Article
- Loss of ENT1 increases cell proliferation in the annulus fibrosus of the intervertebral disc.Journal of cellular physiology · 2019Article
- Adenosine Augmentation Evoked by an ENT1 Inhibitor Improves Memory Impairment and Neuronal Plasticity in the APP/PS1 Mouse Model of Alzheimer's Disease.Molecular neurobiology · 2018Article
- Quantification of the Light Subunit of Neurofilament Protein in Cerebrospinal Fluid of Huntington's Disease Patients.PLoS currents · 2018Article
- The Role of Adenosine Tone and Adenosine Receptors in Huntington's Disease.Journal of caffeine and adenosine research · 2018Review
- Differential gene regulatory networks in development and disease.Cellular and molecular life sciences : CMLS · 2018Review
- Emerging Roles of Nucleoside Transporters.Frontiers in pharmacology · 2018Article
- Article
- The Role of Adenosine ABioMed research international · 2017Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 4 institutions in 4 countries.
Xavier GuitartIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, United States.
Jordi BonaventuraIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, United States.
William ReaIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, United States.
Marco OrrúIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, United States.
Lucrezia CellaiDepartment NEUROFARBA, Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.
Ilaria DettoriDepartment NEUROFARBA, Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.
Felicita PedataDepartment NEUROFARBA, Division of Pharmacology and Toxicology, University of Florence, 50139 Florence, Italy.
Marc BrugarolasDepartment of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona and Center for Biomedical Research in Neurodegenerative Diseases Network and Institute of Biomedicine, 08028 Barcelona, Spain.
Antonio CortésDepartment of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona and Center for Biomedical Research in Neurodegenerative Diseases Network and Institute of Biomedicine, 08028 Barcelona, Spain.
Vicent CasadóDepartment of Biochemistry and Molecular Biology, Faculty of Biology, University of Barcelona and Center for Biomedical Research in Neurodegenerative Diseases Network and Institute of Biomedicine, 08028 Barcelona, Spain.
Ching-Pang ChangDivision of Neuroscience Institute of Biomedical Sciences, Academia Sinica, 11529 Taipei, Taiwan.
Manikandan NarayananSystems Genomics and Bioinformatics Unit, Laboratory of Systems Biology, National Institute of Allergy and Infectious Diseases, Intramural Research Program, National Institutes of Health, Bethesda, MD 20892, United States.
Yijuang ChernDivision of Neuroscience Institute of Biomedical Sciences, Academia Sinica, 11529 Taipei, Taiwan.
Sergi FerréIntegrative Neurobiology Section, National Institute on Drug Abuse, Intramural Research Program, National Institutes of Health, Baltimore, MD 21224, United States. Electronic address: sferre@intra.nida.nih.gov.
National Institutes of Health · USBiomedical Research Networking Center on Neurodegenerative Diseases · ESUniversity of Florence · ITInstitute of Biomedical Sciences, Academia Sinica · TW
Funding
Neurotransmitter Receptor Heteromers in the Striatal Spine ModuleZIADA000493 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI FERRE, SERGI · 2009 to 2025
$35.6MNeurotransmitter Receptor Heteromers in the Striatal Spine ModuleZ01DA000493 · NIDA · NATIONAL INSTITUTE ON DRUG ABUSE · PI GOLDBERG, STEVEN R · 2006 to 2008
$691kIntramural NIH HHS Z01 DA000493
Abstract
The initial goal of this study was to investigate alterations in adenosine A
Indexed as
AdenosineAdenosine A2 Receptor AntagonistsAnimalsBiomarkersCorpus StriatumDisease Models, AnimalGene Expression RegulationHumansHuntingtin ProteinHuntington DiseaseLocomotionNucleoside Transport ProteinsPrefrontal CortexPsychomotor DisordersPurinesRatsAdenosineAdenosine A2 Receptor AntagonistsBiomarkersHtt protein, ratHuntingtin ProteinistradefyllineNucleoside Transport ProteinsPurinesReceptor, Adenosine A2ATriazinesTriazolesTritiumZM 241385A(2A) receptorAdenosineENT1Huntington disease
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.